COVID-19 outcomes in sickle cell disease and sickle cell trait.
Publication/Presentation Date
9-1-2022
Abstract
Throughout the Coronavirus Disease 2019 (COVID-19) pandemic, understanding the effects of COVID-19 on persons with Sickle Cell Disease (SCD) and Sickle Cell Trait (SCT) has garnered interest. Patients with SCD diagnosed with COVID-19 utilize the emergency department and are hospitalized at significantly higher rates compared to the general population, with vaso-occlusive crisis and acute chest syndrome as the leading presentations. Whether SCD alone increases the likelihood of severe COVID-19 illness remains uncertain; however, potential risk factors for severe disease among patients with SCD include older age, frequent acute care visits for pain, haemoglobin SC disease, and pre-existing end-organ disease. SCT status may also influence COVID-19 outcomes, particularly among those with pre-existing co-morbidities. Corticosteroids in patients with SCD and COVID-19 should be used with extreme caution given strong associations between corticosteroid exposure and severe vaso-occlusive crisis, with prophylactic transfusion administered if corticosteroids are deemed necessary. Hydroxyurea may be protective in COVID-19.
Volume
35
Issue
3
First Page
101382
Last Page
101382
ISSN
1532-1924
Published In/Presented At
Christian, J., Lanzkron, S., & Naik, R. P. (2022). COVID-19 outcomes in sickle cell disease and sickle cell trait. Best practice & research. Clinical haematology, 35(3), 101382. https://doi.org/10.1016/j.beha.2022.101382
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
36494153
Department(s)
Administration and Leadership
Document Type
Article